• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verastem, Inc. - Common Stock (NQ:VSTM)

    8.770 +0.160 (+1.86%)
    Streaming Delayed Price Updated: 3:34 PM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Verastem, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Verastem Oncology to Present at Upcoming Investor Conferences
    From Verastem Oncology
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
     
    Via Benzinga
    Curious about the stocks that are showing activity after the closing bell on Wednesday?
    After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
    Via Chartmill
    Earnings Scheduled For August 7, 2025
     
    Via Benzinga
    Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
    From Verastem Oncology
    Via Business Wire
    Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
    From FN Media Group LLC
    Via GlobeNewswire
    Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
    From Verastem Oncology
    Via Business Wire
    Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish
    In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell... 
    Via Stocktwits
    12 Health Care Stocks Moving In Monday's Intraday Session
     
    Via Benzinga
    Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
     
    Via Benzinga
    What's Going On With Verastem Oncology Stock On Monday?
    Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses. 
    Via Benzinga
    Which stocks are experiencing notable movement on Monday?
    Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
    Via Chartmill
    Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present at the Jefferies Global Healthcare Conference
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
    FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments. 
    Via Benzinga
    Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased
    The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian... 
    Via Stocktwits
    FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present at Upcoming Investor Conferences
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces $75 million Private Placement
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
    From Verastem Oncology
    Via Business Wire
    9 Health Care Stocks With Whale Alerts In Today's Session
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.